Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer
about
FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.Squamous cell lung cancer: from tumor genomics to cancer therapeuticsBeyond histology: translating tumor genotypes into clinically effective targeted therapies.Molecular pathways and therapeutic targets in lung cancerMYCxing it up with FGFR1 in squamous cell lung cancer.Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.Current concepts on the molecular pathology of non-small cell lung carcinoma.The Fibroblast Growth Factor signaling pathwayKAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancerMolecularly targeted therapies in non-small-cell lung cancer annual update 2014Global Transcriptomic Profiling of Cardiac Hypertrophy and Fatty Heart Induced by Long-Term High-Energy Diet in Bama Miniature PigsCharacterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.Combined CSL and p53 downregulation promotes cancer-associated fibroblast activationThe clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis.FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway.FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies.Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma.Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.Emerging biomarkers in head and neck cancer in the era of genomics.A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine.A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.Advances and challenges in targeting FGFR signalling in cancer.Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.Relevance of genetic alterations in squamous and small cell lung cancer.Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.Missing the mark in FGFR1-amplified squamous cell cancer of the lung.[Cytological material for molecular pathology].A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.[Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsAugmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients
P2860
Q27852999-035FF66B-EC27-4A9F-AA7B-D8CF0696671EQ28086951-CEAD0A19-02F3-4D4B-852D-CA62B6F0C823Q33560928-8387047A-3E54-40AE-9D59-6818BF5432F2Q33688872-299FA404-67BA-479A-A404-7AB20A910DA1Q33820617-6FCB5704-82C6-448A-BBB9-AB2F45738DA8Q34101045-B315262B-AEBD-482E-ACCD-7023E82DE04EQ34310062-7DCD2F9A-78F1-43D7-866B-24FBA156825AQ34467171-8628B0A5-19D0-4F1F-AA85-69E65412FF19Q34528297-866C8D2A-F1F2-4946-81A0-E1B2E83847B3Q35136424-3EDDFCB8-5BDD-4988-B60C-D5C6C83BBD99Q35687936-554F7936-CD0D-4FEB-8FA3-5CAE9ABDA590Q35932114-FC8FCC8C-727A-4748-9493-9AC77A870117Q36425130-10D28C84-DECD-4417-A09F-7266AE8AB116Q36450685-26E269A9-E5BF-4E3C-A85B-D4D367F6E671Q37046814-A1E7DE9A-AFF8-4FEE-81C8-0FFAFE806C8AQ37164249-DC0D6F2D-6727-4413-B5ED-7BB5A9486007Q37444264-62F12D5F-36F1-43A0-96F3-327E55E68CBEQ37457703-080F9D9A-736A-4156-B739-8787DECBADD3Q38268896-8A566DE0-D08B-410D-B41E-5218D77B3FE2Q38433965-3CE191F0-DD73-4019-9228-C4FDDED59ADEQ38725360-FF42556B-A754-4456-94EE-E4168E0B3F6AQ38729065-AA65DB39-76F6-4486-B3F0-7E774F31E5C0Q38825099-E6C212DF-519E-4A11-A53C-A47F96E41EFFQ39183442-FEEB4807-B16B-4DA2-8C1F-9F4FE1142CA8Q40343596-124AF23F-EC04-496E-B56D-79CB15E18E85Q42738385-7993E7AD-8E56-4C3B-8984-E93CB16152D1Q44483486-6E403D1C-C15B-47FC-93FF-30E53E6328CFQ47715159-78F62D3B-B0E8-4FF6-9B38-AC5B5F921591Q48231295-938E4ED4-C29B-4802-8D57-74C4A9029E81Q49791794-0291EE26-A2BC-4E9C-BA7D-39C292AF20ACQ52863616-133FE38C-FBE4-46DD-A23A-3FF7D391D186Q53813026-EA1A74D2-9541-4832-9035-C8CDBB506AC2Q55034861-A86DBB77-7A23-4F6E-98DC-F8602DCAF962Q55443707-9B8B3964-C1BF-4F05-B688-DFB24420F0A3Q58599659-1549E312-C787-4C9A-83C7-8809FE369E72Q58787276-3629D4B8-E61D-4EE2-BB54-2755D3503C2D
P2860
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@ast
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@en
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@nl
type
label
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@ast
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@en
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@nl
prefLabel
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@ast
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@en
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@nl
P2093
P50
P3181
P1433
P1476
Cell-autonomous and non-cell-a ...... amplified FGFR1 in lung cancer
@en
P2093
Alexandra Florin
André Richters
Danila Seidel
Dennis Plenker
Felix Dietlein
Florian Malchers
Francois Ringeisen
Frauke Leenders
H Christian Reinhardt
Jakob Schöttle
P304
P3181
P356
10.1158/2159-8290.CD-13-0323
P407
P577
2013-12-03T00:00:00Z